Telix Pharmaceuticals Ltd (TLX) stock
TLXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as TLPPF
$8.96+0.11 (+1.19%)
Close on Nov 18, 2026Market cap $3.04BP/E –Yield –
Telix Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was $29.78M, down 46.0% from the year before.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.78M | -46.0% |
| FY2024 | Dec 31, 2024 | $55.18M | +401.2% |
| FY2023 | Dec 31, 2023 | $11.01M | – |
See a number that looks wrong?